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Abstract 
We have previously shown that acute oral exposure to the environmental carcinogen 
benzo(a)pyrene (BaP) elicits comparable levels of DNA adducts, but distinct transcriptomic 
changes, in mouse lungs and livers, the two main BaP bioactivating organs. Oral BaP exposure is 
predominantly associated with lung cancer and not hepatic cancer in some animal models, 
suggesting that gene expression differences may provide insight into the drivers of tissue-specific 
carcinogenesis. In the present study, we examine pulmonary DNA adduct formation, lacZ 
mutant frequency, and mRNA profiles in adult male MutaTMMouse following sub-chronic (28 
day) oral exposure to BaP (0, 25, 50, and 75 mg/kg/day) and sacrificed 3 days post-exposure. 
The results are compared to those obtained from livers of the same mice (previously published). 
Although there was a 1.8- to 3.3-fold increase in the levels of DNA adducts in lung compared to 
liver, the lacZ transgene mutant frequency was similar in both tissues. At the transcriptomic 
level, a transition from activation of the DNA damage response p53 pathway at the low dose to 
the induction of genes involved in angiogenesis, evasion of apoptosis and growth signals at the 
high doses was evident only in the lungs. These results suggest that tissue DNA adducts and 
mutant frequency are sensitive markers of target tissue exposure and mode of action, whereas, 
early changes in gene expression may provide a better indication of the likelihood of 
carcinogenic transformation in selected tissues. Moreover, the study provides new information 
on the underlying mechanisms that contribute to tissue specific responses to BaP. 
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Introduction 
Benzo(a)pyrene (BaP) is a well-studied polycyclic aromatic hydrocarbon (PAH) that is 
found in cigarette smoke, indoor and outdoor air, as well as in charred meats. Metabolic 
activation of BaP by cytochrome P450 (CYP) enzymes, namely CYP1a1 and CYP1b1, results in 
the generation of several BaP metabolites, including BaP-7,8-diol-9,10-epoxide (BPDE), a 
highly reactive form of BaP. BPDE is the primary metabolite of BaP that covalently binds DNA 
and forms DNA adducts (Baird et al., 2005). These DNA adducts, if left unrepaired, can cause 
mutations in genes involved in xenobiotic metabolism, tumour suppression, or oncogenes 
leading to tumour development. The International Agency for Research on Cancer (IARC) has 
recently upgraded their classification of BaP to a Group 1 (i.e., known human) carcinogen (Baan 
et al., 2009). Exposure to BaP leads to tumour formation in animal models, and 
epidemiologically, a link between BaP exposure and cancer incidence in humans has been 
established (OEHHA, 2010). In addition to being carcinogenic and mutagenic, BaP is a known 
immunosuppressant (Dean et al., 1983). BaP can also alter cell cycle progression (Solhaug et al., 
2005), induce inflammation (Qamar et al., 2012), and impair DNA repair and apoptotic 
processes (Solhaug et al., 2005) leading to aberrant cellular functioning. 
The primary site of BaP metabolism is the liver; however, hepatocarcinogenesis is rare in 
humans and inconsistent in animals (OEHHA, 2010). Lung carcinogenesis, on the other hand, is 
prevalent in mice exposed orally to BaP (Stoner et al., 1984;  Wattenberg and Leong, 1970), 
including MutaTMMouse (Hakura et al., 1998). This is explained by greater BaP retention in the 
lung (Galván et al., 2005;  Harrigan et al., 2004), higher induction of CYP1a1 and CYP1b1 in 
the lung tissue (Harrigan et al., 2006), and higher levels of BPDE-DNA adducts in the lungs 
compared to the liver (Harrigan et al., 2004). Indeed, the levels of BaP-induced DNA adducts in 
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any tissue at a given time is a function of metabolic conversion of BaP to its DNA-reactive 
metabolites via phase I xenobiotic metabolism, phase II detoxification, the rate of adduct repair, 
and the cell turnover rate, collectively suggesting that tissue dynamics and BaP response between 
lung and liver tissues likely differs.  
Our previous work examined global gene expression changes in the lungs of adult male 
mice following acute exposure to 150 and 300 mg/kg BaP by oral gavage for three consecutive 
days and sacrificed four hours post-exposure (Halappanavar et al., 2011). The pulmonary 
transcriptomic response included changes in biological pathways involved in B-cell receptor 
(BCR) signalling, inflammation, and DNA damage response. We also noted that the response in 
the lung tissue was different, and in some respects, much more pronounced than livers from the 
same mice. Oxidative stress, xenobiotic metabolism, aryl hydrocarbon receptor (AhR) signalling, 
and glutathione metabolism were among the common pathways that were affected in both 
tissues, whereas negative regulation of the BCR signalling, indicative of potential primary 
immunodeficiency, was unique to the lung tissue. However, both tissues exhibited similar levels 
of DNA adducts, suggesting that evidence of higher levels of tissue DNA adducts are not 
sufficient to predict the observed transcriptomic differences in lungs and livers. Although the 
study was conducted at very high doses of BaP, the findings support the hypothesis that tissue-
specific mechanisms are at work, and that differential regulation of the known biological 
pathways associated with cancer formation could explain the selective targeting of lungs for 
carcinogenesis.  
In the present study, we explore further the potential of early BaP-induced gene 
expression changes to identify the tissue-specific events that may eventually lead to carcinogenic 
transformation following BaP exposure. We globally profile the pulmonary transcriptome and 
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measure in parallel the induced frequency of mutations and DNA adducts (known predictors of 
genotoxicity-mediated cancer) in the lung tissues of adult male mice repeatedly exposed to 25, 
50 and 75 mg/kg BaP for 28 consecutive days by oral gavage and sacrificed three days post-
exposure. The results are compared and interpreted in light of the differential biological 
responses reported for the lungs and livers of mice following both acute (Halappanavar et al., 
2011;  Yauk et al., 2011) and sub-chronic (Malik et al., 2012) exposures to BaP.  
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Materials and Methods 
Animal Treatment 
Adult (25 weeks-old) male MutaTMMouse (transgenic mouse strain 40.6) were exposed to 
BaP (Sigma Aldrich, Canada) as described previously (Malik et al., 2012). In brief, animals were 
dosed daily via oral gavage for 28 days with varying doses of BaP (0, 25, 50, 75 mg/kg body 
weight/day) dissolved in olive oil. Each dose group contained five animals. Mice were sacrificed 
by cardiac puncture under isofluorane anaesthesia 72 hours following the final exposure. The 
right lobe of the lung was excised, flash frozen in liquid nitrogen, and stored at −80°C until use. 
For the duration of the experiment, food (2014 Teklad Global standard rodent diet) and water 
were provided ad libitum and mice were caged individually in plastic film isolators (Harlan 
Isotec, UK) on a 12 hour light/12 hour dark cycle. Mice were bred, maintained and treated in 
accordance with the Canadian Council for Animal Care Guidelines and approved by Health 
Canada’s Animal Care Committee. 
Tissue Selection 
The major exposures to BaP occur via the oral route (drinking and feed) (Hettemer-Frey 
and Travis, 1991). The organs directly affected by BaP as a consequence of oral exposure 
include stomach, esophagus, tongue, and larynx (Culp et al., 1998). However, studies conducted 
by Stoner et al. (1984) and Wattenberg and Leong (1970) show lung and liver to be equally 
impacted by BaP (oral gavage) and moreover, revealed sensitivity of lung for tumour 
development in comparison with liver. In alignment with these reports, our previous work 
(Halappanavar et al., 2011;  Yauk et al., 2011) revealed lung-specific regulation of the biological 
processes known to be associated with cancer formation. Thus, in the present study we have 
investigated transcriptional responses in lung and liver. The results of the study may also help 
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address the importance of considering the multi organ toxicity in calculating the risk associated 
with chemicals, such as BaP.  
Tissue DNA Extraction 
The frozen lung and liver tissue was sliced randomly. Genomic DNA was isolated from a 
random tissue section for measuring the levels of DNA adducts and transgene mutant frequency. 
In brief, lung tissue was minced and de-gassed to remove all traces of air in the alveoli. Livers 
were homogenized in ice cold TMST buffer (50 mM Tris, pH 7.6, 3 mM magnesium acetate, 250 
mM sucrose, 0.2% Triton X-100) as described in Douglas et al. (1994). The minced tissue was 
washed twice in cold phosphate buffered saline and lysed in 10 mM Tris pH7.6, 10 µM EDTA, 
100 µM NaCl, 1% SDS overnight at 37°C on a rotating platform. The lysate was digested with 
proteinase K (1 mg/ml lysis buffer). DNA was isolated using a serial phenol/chloroform/isoamyl 
alcohol (25:24:1) and chloroform/isoamyl alcohol (24:1) extraction (Renault et al., 1997). DNA 
was precipitated in ethanol and dissolved in Tris-EDTA buffer (10 mM Tris pH7.6, 500 mM 
EDTA). DNA was stored at 4°C until use. 
DNA Adduct Analysis 
DNA adduct formation in each sample was determined using the nuclease P1 digestion 
enrichment version of the 32P-postlabelling assay as described previously (Phillips and Arlt, 
2007) with minor modifications. Briefly, 4 µg of DNA was digested overnight with micrococcal 
nuclease (288 mUnits, Sigma, cat. no. N3755) and calf spleen phosphodiesterase (1.2 mUnits, 
MP Biomedicals, cat. no. 100977), enriched and labelled as described elsewhere (Phillips and 
Arlt, 2007). Radiolabelled adducted nucleotide biphosphates were separated by thin-layer 
chromatography on polyethyleneimine-cellulose plates (Macherey-Nagel, Düren, Germany) with 
the following chromatographic conditions (Arlt et al., 2008): D1, 1.0 M sodium phosphate, pH 6; 
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D3, 4.0 M lithium-formate, 7.0 M urea, pH 3.5; D4, 0.8 M LiCl, 0.5 M Tris, 8.5 M urea, pH 8. 
Chromatographs were scanned using a Packard Instant Imager (Dowers Grove, USA) and DNA 
adduct levels (relative adduct labelling) were calculated from the adduct counts per minute 
(cpm), the specific activity of [γ-32P]ATP, and the amount of DNA (pmol of DNA-P) used. An 
external BPDE-DNA standard was used for identification of BaP-DNA adducts. Results are 
expressed as DNA adducts/108 nucleotides. 
LacZ Mutant Frequency (Positive Selection) 
The transgene lacZ mutant frequency in lungs was determined using the P-gal (phenyl-ß-
D-galactopyranoside) positive selection assay as described in Vijg and Douglas (1996) and 
Lambert et al. (2005). The λgt10lacZ DNA was rescued from the genomic DNA using the 
TranspackTM lambda packaging system (Stratagene, USA). The packaged phage particles were 
mixed with host bacterium (Escherichia coli lacZ-, galE-, recA-, pAA119 with galT and galK), 
plated on minimal medium containing 0.3% (w/v) P-Gal and incubated overnight at 370C. Total 
plaque-forming units (pfu) were measured on concurrent titres that did not contain P-Gal. Mutant 
frequency is expressed as the ratio of the number of mutant pfu to total pfu. Mutant frequency 
data analysis was performed as described previously (Malik et al., 2012). 
RNA Extraction and Purification 
Total RNA was isolated for gene expression analysis and qRT-PCR validation as 
described previously (Halappanavar et al., 2011). Briefly, total RNA was extracted from the 
lungs using TRIzol reagent (Invitrogen, USA) and purified using RNeasy Mini Kit (Qiagen, 
Canada). The RNA quantity and purity was checked using a Nanodrop Spectrophotometer 
(Thermo Fisher Scientific, Canada). The RNA integrity was determined using an Agilent 2100 
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Bioanalyzer (Agilent Technologies, Canada). The samples showing A260/A280 ratios between 2.1 
and 2.2 and having RNA Integrity Number above 7.5 were used for further analysis.  
Microarray Hybridization and Analysis 
Double-stranded cDNA and cyanine-labelled cRNA was synthesized (Agilent Linear 
Amplification Kits, Agilent Technologies, Canada) from 250 ng of total RNA from each sample 
and universal reference total RNA (Stratagene, Canada). Cyanine-labelled cRNA targets were in 
vitro transcribed using T7 RNA polymerase and purified by RNeasy Mini Kit (Qiagen, Canada). 
From each (sample and reference) labelled sample 825 ng of cRNA was hybridized to Agilent 
4X44K oligonucleotide microarrays (Agilent Technologies, Canada) at 60°C overnight (16 
hours) in the Agilent SureHyb hybridization chamber. Arrays were washed and scanned on an 
Agilent G2505B Scanner according to manufacturer’s recommendations. Feature extraction 
software version 10.7.3.1 (Agilent Technologies, Canada) was used to extract the data.  
 A reference design (Kerr and Churchill, 2001) was used to analyse mRNA expression as 
described previously (Malik et al., 2012). All analyses were conducted in the R (R-Development-
Core-Team, 2010) environment using the MAANOVA library (Wu, 2010). The background 
fluorescence was measured using the negative control (-)3xSLv1 probes; probes with median 
signal intensities less than the trimmed mean (trim = 5%) plus three trimmed standard deviations 
of (-)3xSLv1 probe were flagged as absent (within the background signal). Probes were 
considered present if at least four of the five samples within a condition had signal intensities 
greater than three trimmed standard deviations above the trimmed mean of the (-)3xSLv1 probes 
(background signal). Data were normalized using the transform.madata() function using the 
glowess option with a span of 0.1. Ratio intensity plots and heat maps for the raw and 
normalized data were constructed to identify outliers. One sample (50 mg/kg group) was 
 10
removed from the analysis based on clustering. The statistical model for this analysis included 
fixed effects of array and treatment condition and was applied to the log2 of the absolute 
intensities. Differentially expressed transcripts (upregulated or downregulated relative to olive 
oil treated control mouse lung samples) were determined using the Fs statistic option in the 
matest() function. The p values for all statistical tests were estimated by the permutation method 
with residual shuffling and false discovery rate (FDR) adjusted p values were estimated using the 
adjPval() function. The fold change calculations were estimated as described previously (Malik 
et al., 2012). Significant genes were selected based on a FDR adjusted p value < 0.05 for any 
BaP exposed versus control contrast.  
qRT-PCR Array Validation 
Mouse pathway-specific PCR array (cancer-PAMM-033, SABiosciencesTM, USA) and 
custom PCR arrays consisting of 172 genes in total were employed to validate the microarray 
results. Genes for the custom array were selected based on their implication in biological 
processes relevant to lung carcinogenesis. These genes included statistically significant 
differentially expressed genes (FDR adjusted p < 0.05), differentially expressed genes that 
exhibited high fold changes (fold rank only) but were not statistically significant, and genes that 
were differentially regulated (FDR adjusted p < 0.05) in the livers from the same mice (Malik et 
al., 2012). In brief, 0.8 µg of total lung tissue RNA (n=5/group) from each sample was reverse 
transcribed using RT2 First Strand Kit (SABiosciencesTM, USA). Real-time PCR was performed 
using RT2 SYBR Green PCR Master Mix on a CFX96 real-time detection system (Bio-Rad, 
Canada). Threshold cycle values for each well were averaged. Relative gene expression was 
determined according to the comparative Ct method and normalized to reference RNAs Hprt1, 
Gapdh, and Actb housekeeping genes for the Cancer Pathway array and to reference RNAs Gusb 
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and Hprt1 housekeeping genes for the custom arrays. Transcripts were further normalized by 
subtracting the median delta Ct value for each sample. Differential expression was determined 
with a two-sample bootstrap test using R software (R-Development-Core-Team, 2010). The fold 
change was estimated using the ratio of the arithmetic mean of the treated sample to the mean of 
the control samples. Standard errors for the fold change values were estimated using the 
bootstrap test (Efron and Tibshirani, 1993). 
Bioinformatics 
All mRNA data are deposited in the NCBI Gene Expression Omnibus database under 
accession numbers GSE35718 (lung) and GSE24910 (liver). Following normalization, biological 
functions perturbed in response to BaP were identified using functional annotation clustering in 
the Database for Annotation, Visualization and Integrated Discovery (DAVID) (Huang da et al., 
2009) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and Goto, 2000). 
The biological and molecular functions of genes that were significantly differentially expressed 
(FDR adjusted p ≤ 0.05, or FDR adjusted p ≤ 0.1 and fold change ≥ 1.5) following exposure to 
BaP treatment were analysed and explored in IPA (Ingenuity® Systems, Redwood City, CA). 
Molecular relational networks of genes modulated by BaP in lung tissue enriched for cancer 
function were generated using IPA. Each molecule was overlaid onto a global molecular network 
developed from information contained in the Ingenuity Knowledge Base. Networks were 
generated based on their connectivity. All relationships are supported by at least one reference 
from the literature.  
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Results 
Daily exposure to 25, 50, and 75 mg/kg BaP for 28 consecutive days caused no overt 
signs of toxicity and there was no significant body weight loss in any of the exposed mice 
compared to vehicle treated controls.  
BaP-induced DNA adduct formation in lung and liver tissue 
The presence of DNA adducts indicates the development of pre-mutagenic lesions 
following a chemical exposure. The 32P-postlabelling technique was employed to measure BaP-
induced DNA adducts in the lung tissues of mice exposed to 0, 25, 50, and 75 mg/kg BaP for 28 
consecutive days (Figure 1a). BaP-7,8-diol-9,10-epoxide-N2-deoxyguanosine (dG-N2-BPDE) 
was identified as the main adduct as reported previously (Lemieux et al., 2011). No adducts were 
detected in mice dosed with vehicle control. DNA adduct formation by BaP was dose-dependent. 
Although liver DNA adducts were analyzed in these samples previously (Lemieux et al., 2011;  
Malik et al., 2012), these data were not used. Instead, 32P post-labelling was repeated in these 
samples in order to ensure that the protocols in both liver and lung were identical and performed 
in the same lab. Similar to results observed in the lungs, dG-N2-BPDE was the main adduct 
identified in liver, and adduct levels increased in a dose-dependent manner (Figure 1a). 
However, the frequency of DNA adducts in liver was significantly lower than in lung tissue for 
each dose (Bonferonni-corrected p value ≤ 0.05), suggesting that lung tissue is more susceptible 
to DNA damage caused by BaP.  
 
Mutagenic activity of BaP in the lung tissue 
The MutaTMMouse contains around 29 +/- 4 (Shwed et al., 2010) copies of λgt10lacZ 
shuttle vector stably integrated in the mouse genome, thus permitting in vivo lacZ mutant 
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frequency analysis. In agreement with the DNA adduct results, a dose-dependent increase in 
mutant frequency was observed (Figure 1b) in lung tissues. Compared to the vehicle controls, a 
5.2-, 13- and 18.6-fold increase was seen in the 25, 50 and 75 mg/kg dose groups, respectively. 
Mice gavaged with pure olive oil (vehicle) yielded a low spontaneous lacZ mutant frequency. No 
significant differences between the lung and liver tissues were observed for lacZ mutant 
frequency.  
 
General overview of pulmonary gene expression profiles 
Repeated oral gavage of mice with BaP induced significant changes in the expression of 
many genes in the lung tissue. MAANOVA analysis revealed 20, 145, and 373 unique probes 
that were differentially expressed (up or downregulated) with a fold change ≥ 1.5 in either 
direction, and an FDR adjusted p ≤ 0.05 in the 25, 50 and 75 mg/kg exposure groups compared 
to controls, respectively (Supplementary File 1). The complete lung microarray dataset is 
available through the Gene Expression Omnibus at NCBI (http://www.ncbi.nlm.nih.gov/geo/), 
accession number GSE35718. Hierarchical cluster analysis on all differentially expressed genes 
(FDR p ≤ 0.05, fold change ± 1.5) revealed that all treatment groups clustered separately from 
the control (Supplementary File 2), thus, a clear treatment effect was observed as a result of 
exposure to BaP. 
Among the differentially expressed genes, 297 were upregulated and 90 were 
downregulated. Cyclin-dependent kinase inhibitor 1A (Cdkn1a), growth differentiation factor 15 
(Gdf15), carboxylesterase 5 (Ces5), pleckstrin homology-like domain, family A, member 3 
(Phlda3), multimerin 2 (Mmrn2), cyclin G1 (Ccng1), serum amyloid A 3 (Saa3) and sestrin 2 
(Sesn2) were the most upregulated genes in all the dose groups. The most downregulated genes 
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included Sarcolipin (Sln), myomesin 2 (Myom2), tropomyosin 1, alpha (Tpm1α) in the 75 mg/kg 
group, chitinase 3-like 3 (Chi3l2) and gastrin releasing peptide (Grp) in the 50 mg/kg  group, and 
sineoculis-related homeobox 1 homolog (Six1) (Drosophila) and ras homolog gene family, 
member U (Rhou) in the 25 mg/kg dose group. Twenty-five probes representing 23 genes were 
commonly altered between the dose groups with an FDR p ≤ 0.05 in at least one dose group 
(Table 1). The observed transcriptomic response was dose-dependent. 
Gene ontology analysis was employed to assign biological processes and functional 
categories to significant genes (FDR p ≤ 0.05, fold change ≥ 1.5) in DAVID. Biological 
functions perturbed in response to BaP were identified using functional annotation clustering in 
DAVID (Supplementary File 3a). Significant functional enrichment (score > 2.0) was found for 
biological processes including extracellular signalling, cell adhesion, angiogenesis, apoptosis, 
and regulation of cell growth in all dose groups. Further combined analysis employing DAVID 
and KEGG pathways revealed that the altered genes are associated with specific biological 
pathways, including p53 signalling, molecular mechanisms of cancer, small cell lung cancer, 
extracellular membrane receptor interaction, and focal adhesion (Supplementary File 4a).  
In addition to the analysis described above, we relaxed the FDR adjusted p value to 
include genes that exhibit FDR p ≤ 0.1 and fold change ≥ 1.5 to see if we had missed any 
important genes in the pathways described above as a consequence of the stringent MAANOVA 
analysis. Using this criterion, 47, 181, and 429 genes in the 25, 50, and 75 mg/kg dose groups, 
respectively, were differentially altered. Fifty-one additional genes were identified by relaxing 
the p-value cut-off (Supplementary File 6). DAVID analysis (Supplementary File 3b and 4b) as 
described above revealed three new functional categories: cell-to-cell and cell-to-matrix 
interactions, protein maturation, and inflammatory response. An in-depth functional analysis 
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using IPA on these genes (FDR p ≤ 0.1 and fold change ≥ 1.5) revealed that the altered genes 
were associated with multiple functions, such as cancer, cell death, cell cycle, cellular growth 
and proliferation, cellular movement, DNA replication and repair, inflammatory response, and 
tumour morphology (Figure 2a). Since the present work is focused on finding perturbations in 
pathways associated with carcinogenic transformation in the lung tissue, a sub-analysis on 
specific genes that were grouped under the functional group ‘cancer’ was performed. The sub-
analysis revealed that a majority of the genes from this group were mainly associated with the 
p53 signalling pathway and were implicated in several biological processes regulated by p53, 
such as cell cycle arrest, apoptosis, inhibition of cellular growth and proliferation, and DNA 
repair. Many of these genes were common across the dose groups (Tables 1, 2, and 3) and 
showed a clear dose-response. The other affected pathways included the molecular mechanisms 
of cancer, AhR signalling, BCR signalling, and angiogenesis (Table 3). A similar functional 
analysis using IPA on liver (Malik et al., 2012) revealed that the altered genes were associated 
with lipid metabolism, cancer, molecular transport, inflammatory response, and cell death 
(Figure 2b). Sub-analysis of the cancer-associated genes in the liver reveals that in addition to the 
p53 signalling pathway, this category includes genes involved in metabolism and inflammation, 
which are indirectly linked to carcinogenesis.  
Visualization of the relationship between these genes in a biological network created in 
IPA (Figure 3) revealed that at the low dose the immediate downstream effectors of p53, such as 
Cdkn1a, Ccng1, Bax, and Tp53inp1 mainly involved in DNA damage recognition, cell cycle 
arrest, and apoptosis were upregulated. However, with increasing dose, genes known to be the 
suppressors of p53 signalling pathway, such as Mdm2 were upregulated along with other genes 
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implicated in proliferation and growth, evasion of apoptosis, promotion of angiogenesis, and cell 
invasion and metastasis pathways, all of which are the hallmarks of cancer.  
RT-PCR validation of microarray results 
Exposure to BaP resulted in altered expression of a number of genes involved in the 
molecular mechanisms of cancer (Table 3). Perturbation of this pathway was confirmed using a 
cancer pathway-specific PCR array (Mouse Cancer Pathway Finder PCR array, 
SABiosciencesTM) containing 84 genes. In addition, 61 more genes implicated in BCR 
signalling, calcium signalling, TGFβ signalling, cell cycle, and DNA damage repair pathways 
were also analysed (Table 3). From each dose group five individual samples were analysed.  
In total, 57 of the 145 genes were differentially expressed with p ≤ 0.1 in at least one 
treatment group compared to controls (Table 3, Supplementary File 5); 23 of these correlated 
with the microarray results. Thirty-one genes were significantly differentially expressed as 
measured by the PCR arrays but not by microarrays. This is presumably due to the enhanced 
dynamic range and sensitivity of RT-PCR. These genes included baculoviral IAP repeat-
containing 5 (Birc5), tumour necrosis factor receptor superfamily member 1A (Tnfrsf1a), jun 
proto-oncogene (Jun), c-fos-induced growth factor (Figf), insulin-like growth factor 1 (Igf1), 
interferon beta 1 fibroblast (Ifnb1), vascular endothelial growth factors a and c (Vegfa and 
Vegfc), plasminogen activator urokinase (Plau), integrin alpha 3 (Itga3), platelet-derived growth 
factors a and b (Pdgfa and Pdgfb), and transforming growth factor beta 1 (Tgfb1) (Table 3).  
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Discussion 
BaP is the only PAH classified by IARC as a known human carcinogen (Baan et al., 2009). 
The ability to induce DNA damage and mutations in key genes involved in tumour suppression 
or tumour promotion is one of the postulated mechanisms of BaP-induced carcinogenesis 
(Denissenko et al., 1996;  Ross and Nesnow, 1999). The metabolic activation of BaP by phase I 
CYP enzymes is a prerequisite for its potentially carcinogenic interaction with DNA (Arlt et al., 
2008;  Rubin, 2001). Several clinical and epidemiological studies have shown a link between the 
levels of DNA adducts and exposure-induced carcinogenesis (Gunter et al., 2007;  Tang et al., 
2001). Thus, the presence of DNA adducts may be a risk factor for developing cancer. Although 
many tissues are capable of metabolizing BaP to its carcinogenic intermediate, which is 
associated with the development of mutations, carcinogenesis is specific to certain tissues. For 
example, BaP is predominantly metabolized in the liver; however, hepatocarcinogenesis is 
relatively less frequent in some experimental animal models and in humans compared to 
pulmonary carcinogenesis (Hakura et al., 1998;  Stoner et al., 1984;  Wattenberg and Leong, 
1970). Several factors are suggested to play a vital role in the tissue-specific transformation 
process, including a balance between the metabolic activation and detoxification processes and 
the relative rates of DNA damage, DNA repair and individual susceptibility.  
The presence of tissue DNA adducts and genetic mutations in genes is often used as a 
measure of the carcinogenic potential of a chemical (Mei et al., 2006;  Wang et al., 2011). 
Although these markers of exposure and effect, respectively, classify a chemical as genotoxic 
and non-genotoxic, they may not accurately predict with certainty their carcinogenic potential. 
We have recently shown that acute exposure to BaP by oral gavage leads to similar levels of 
DNA adducts in the lungs and livers, two BaP bioactivating organs (Halappanavar et al., 2011). 
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However, despite similar levels of DNA damage (reflective of bioavailable BaP) in both the 
tissues, the transcriptomic responses in lungs were different and included lung-specific 
perturbations of several biological pathways associated with molecular mechanisms of cancer 
(Halappanavar et al., 2011). The present study was undertaken to further explore the molecular 
mechanisms underlying such distinct tissue-specific responses and their implication in cancer 
formation employing a sub-chronic exposure model. 
In agreement with the published literature (Baird et al., 2005), we found that daily exposure 
to BaP for 28 days resulted in significant genotoxicity as measured by a dose-dependant increase 
in DNA adduct formation and lacZ transgene mutant frequency in the lungs of exposed animals 
(Figure 1). Compared to the livers from the same mice there was a statistically significant 1.8- to 
3.3-fold increase (Bonferonni-corrected p value ≤ 0.05) in DNA adduct formation in the lung 
tissues. In alignment with these results, mRNA expression of DNA polymerase Kappa (PolK), 
necessary for the error-free bypass of the (+)-trans-BPDE-N2-dG DNA adduct (Ogi et al., 2002), 
was significantly upregulated in the lungs (Table 3) but not the liver. In contrast, levels of DNA 
adducts in liver and lung were comparable in C57BL/6 mice acutely exposed to very high doses 
of BaP (Halappanavar et al., 2011) (i.e., 150 mg/kg and 300 mg/kg BaP per day for three days, 
sampled 4 and 24 hours after the last exposure). The discrepancy in DNA adduct levels between 
the acute and sub-chronic repeated dose study could be simply be due to the amount of total BaP 
gavaged over time. Compared to the hepatic tissue, rate of clearance of BaP from the lungs 
occurs slowly resulting in longer retention of BaP in lungs (Harrigan et al., 2004), suggesting 
that the repeated exposure to BaP over 28 consecutive days may have led to accumulation of BaP 
in lungs resulting in higher DNA adduct levels. Studies have shown accumulation of DNA 
adducts in some organs that are resistant to repair or following chronic repeated exposures. It has 
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also been suggested that at higher doses metabolic activation/detoxification of BaP could reach a 
threshold, which in turn may limit the speed with which reactive metabolites are detoxified in the 
organ compared to the speed of the translocation of these metabolites from the primary site (e.g., 
liver) to other distant organs (e.g., lungs) .  
Although we report significant differences in DNA adduct formation between the lung and 
liver, the transgene mutant frequency in both tissues was not significantly different, which may 
suggest more efficient DNA repair in the lungs compared to livers (Fig 2, high dose). The 
elevated mutant frequency observed in livers could be attributed to the higher rates of cellular 
metabolism (as reflected by the number of differentially altered genes in metabolic pathways) 
potentially resulting in an increase in by-products of reactive oxygen species. These results 
suggest that in addition to mutations arising as a result of unrepaired bulky DNA adducts, other 
factors such as alterations in critical molecular processes implicated in cancer formation may 
play a role in the selective targeting of the lung tissue for carcinogenesis following BaP 
exposure.  
Our previous work (Halappanavar et al., 2011) on mice acutely exposed to BaP revealed 
suppression of B-cell receptor (BCR) signalling pathway and an elaborated DNA damage 
response in the lungs, whereas the livers from the same mice showed subtle changes in only a 
few genes associated with DNA damage response (Halappanavar et al., 2011). Repressed BCR 
signalling, leading to primary immunodeficiency, is potentially implicated in cancer initiation 
(Jumaa et al., 2005). In the present study we observed similar suppression of a few of the key 
genes in the BCR signalling pathway in the lungs. However, the response was only observed in 
the high dose group (Table 2), suggesting that the collective downregulation of the BCR 
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signalling pathway may be a potential mechanism that operates in the lungs following exposure 
to high doses of BaP over a very short period of time.  
Exposure to BaP for 28 consecutive days induced a large transcriptomic response in the 
lungs sampled 3 days post-exposure compared to the livers. MAANOVA analysis of liver tissue 
revealed differential expression of 6, 7, and 121 unique probes compared to 20, 145, and 373 
probes in the lungs, in the 25, 50 and 75 mg/kg exposure groups respectively (Malik et al., 2012). 
The p53 signalling pathway was commonly affected in both tissues (Table 2 and 5) (Malik et al., 
2012). P53 is a tumour suppressor protein and mutations in the TP53 gene have been found in 
many types of human cancers linked to environmental exposures (Kucab et al., 2010) including 
lung cancers. The p53 protein is a transcription factor that mediates expression of several genes, 
including Cdkn1a, an inhibitor of cyclin-dependent kinases, Bax, a pro-apoptotic gene, Gadd45, 
a DNA damage repair gene, which is also involved in cell cycle arrest, and many inflammatory 
modulators and growth factors. Transgenic mice devoid of TP53 gene (p53 knockout) or mice in 
which p53 activity is chemically inhibited, exhibit increased susceptibility to develop 
spontaneous and chemically induced tumours (Donehower et al., 1992). Cellular DNA damage 
response to BaP is regulated by p53 (Park et al., 2006). Furthermore, increased rates of lung 
cancer following exposure to BaP arise in transgenic mice expressing lung-specific dominant-
negative mutant p53 (Tchou-Wong et al., 2002), suggesting an important role for the p53 
signalling pathway in the development of BaP-induced lung cancer.  
Since the focus of the present study was to understand the molecular perturbations in lungs 
that are associated with tissue-specific tumour development (i.e, relative to the liver), we 
compared the expression changes of several genes in KEGG pathways associated with cancer in 
both tissues. Table 4 shows a list of 41 genes whose expression was significantly differentially 
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expressed (FDR p ≤ 0.05, fold change ≥ 1.5) in lungs but not in the livers. These genes are 
known for their function in biological pathways such as apoptosis, cell cycle, cytokine-cytokine 
receptor interaction, extracellular membrane receptor interactions, focal adhesion, mitogen-
activated protein kinase (MAPK) signalling, p53 signalling, peroxisome proliferating agent 
receptor (PPAR) signalling, transforming growth factor beta (TGFβ) signalling, and Wnt 
signalling. In contrast, the liver showed expression changes in fewer genes, and these were 
mainly the downstream effectors of p53 signalling; Apaf1, Trp63, MyoD, Egr1, and Btg2 
involved in induction of apoptosis and negative regulation of cellular proliferation. Distinctly 
affected in the lungs were Sestrin 2 (Sesn2), Pmaip1, and Trp53inp1, associated with the p53-
mediated DNA damage response, Mdm2, involved in the negative regulation of p53 signalling, 
and Bcl2, implicated in cell survival.  
Carcinogenic transformation in the lung following BaP exposure appears to be a dose-
dependent process. Figure 3 is a molecular relational network consisting of differentially altered 
genes in lung tissues enriched for cancer function (using IPA functional categorization) in 
response to BaP exposure in our model. Interestingly, nearly all genes in the network were found 
directly or indirectly connected to the transcription factor p53, which is the main node in the 
network. At the lowest dose, genes associated with an early response to DNA damage, such as 
Cdkn1a and Ccng1 involved in cell cycle arrest and Bax and Tp53inp1 involved in the apoptotic 
process, were upregulated, indicating cellular efforts to halt replication until the damage is 
repaired. With increasing dose, the p53 DNA damage response pathway continued to be 
activated. However, activation of pathways and genes implicated in silencing p53 function also 
became evident. This silencing may be related to AhR-dependent induction of Mdm2 expression 
(Pääjärvi et al., 2005), which is a negative regulator of p53 signalling; Mdm2 was upregulated in 
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the two higher doses. While an apparent dose-dependent transition in the p53 DNA damage 
response pathway was observed, at the highest dose many genes involved in angiogenesis 
(Angpt2, Bdnf, Cyr61), evasion of apoptosis (Bcl2l1, Cryab, Lcn2, Rela), growth signals (Pdgfb, 
Pdgfd, Itga1, Notch4) and invasion and metastasis (Il1b, Mmp3, Pdgfra, Shh) were upregulated. 
These high dose effects are indicative of a shift in the fine cellular dynamics from a protective 
repair mode to a cellular replication and proliferation mode, which may suggest cellular 
transformation, potentially a key event in the progression to lung carcinogenesis.  
One limitation of the present study is that the responses were investigated in whole tissue. 
The observed changes reflect the responses of over 40 different cell types. It is clear from the 
lung DNA adduct and mutant frequency data that the observed changes in molecular pathways 
are the direct results of BaP metabolism in the lung tissue. However, it should be noted that the 
influence of circulating factors from other target sites may also contribute to the pulmonary 
responses. 
 In conclusion, we show that the BaP-induced DNA adduct levels in lung tissue are 
comparatively higher than in livers after 28 consecutive days of exposure to increasing doses of 
BaP by oral gavage. However, the occurrence of fixed mutations was comparable in both tissues 
suggesting that for certain carcinogens traditional markers of genotoxicity, i.e., tissue DNA 
adduct levels and mutant frequency may only predict the exposure to the carcinogen and not the 
carcinogenic outcome. In contrast, dose-dependent transition in p53 DNA-damage response 
pathway that included tissue protective (adaptive) responses at the lowest dose (for e.g., genes 
involved in cell cycle and apoptosis) to growth and proliferative responses at the highest dose 
(e.g., growth signals and pro-proliferation) was distinct to lungs only, suggesting such key 
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biological pathway perturbations occurring early after the exposure may be causal to 
carcinogenesis in lungs compared to livers. 
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SUPPLEMENTARY FILE DESCRIPTIONS  
 
Supplementary File 1. Significant gene list. 
List of all significantly differentially expressed genes in at least 1 treatment group (FDR p ≤ 
0.05, fold change ≥ 1.5) in response to repeated oral exposure to 25, 50, and 75 mg/kg/day BaP. 
The list is sorted from highest to lowest fold change in the 75 mg/kg/day treatment group.  
 
Supplementary File 2. Hierarchical cluster analysis.  
Hierarchical cluster analysis of all samples on differentially expressed genes. The heat map 
represents all genes that were statistically significant and differentially expressed in any of the 
treatment groups relative to control mice. Green bars represent low expression levels and red 
represent high expression levels relative to the reference channel. Black bars are similar to the 
reference channel. The heat map was generated using GeneSpring (Agilent Technologies). 
Clusters are color-coded: controls red, 25 mg/kg blue, 50 mg/kg brown, 75 mg/kg grey.  
 
Supplementary File 3. Gene ontology analysis.  
List of the most enriched functional annotation clusters using DAVID based on significantly 
differentially expressed genes in at least one dose with an FDR adjusted p ≤ 0.05 (a) or FDR 
adjusted p ≤ 0.1 (b) and fold change ≥ 1.5. Each cluster groups similar annotations together to 
clarify the biological function. The names given to each annotation were arbitrarily chosen based 
on the constituents of the cluster. The Enrichment Score is the geometric mean of the p values of 
the cluster constituents transformed by -log. The p value is the EASE score which is a modified 
Fisher Exact p value. 
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Supplementary File 4. Pathway analysis.  
Functional annotation into KEGG pathway categories using significantly differentially expressed 
genes with an FDR adjusted p value ≤ 0.05 (a) or FDR adjusted p value ≤ 0.1 (b) and fold change 
≥ 1.5 in at least one dose group. The pathway annotations displayed have an EASE score (one-
tail Fisher Exact p value) less than 0.1. 
 
Supplementary File 5. PCR validation.  
All genes validated by qRT PCR using PCR arrays in lungs from BaP exposed mice. Bold genes 
are validated from microarrays. Genes colored in grey had low expression in both the dose 
groups and control (Ct>30). 
 
Supplementary File 6. Relaxed gene list.  
List of genes additionally differentially expressed following relaxing of the significance cut-off 
from FDR p < 0.05 to FDR p < 0.1. P values shown are FDR adjusted. 
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FIGURE LEGENDS 
 
Figure 1 
DNA adduct formation (a) and lacZ mutant frequency (b) in the lungs and livers from 
MutaTMMouse sub-chronically exposed to BaP. Levels of BaP-7,8-diol-9,10-epoxide-N2-
deoxyguanosine (dG-N2-BPDE) adducts were determined using the nuclease P1 enrichment 
version of the 32P post-labelling method. Data are represented as average ± standard error of the 
mean (n = 5 mice/group). ND, not detected. Average lacZ mutant frequency was determined 
using the P-Gal positive selection assay. Values shown are average frequencies x 105 ± standard 
error of the mean. Asterisk (*) indicates significance by Student’s t-test (p < 0.01) compared to 
controls. Transgene mutant frequency data for the liver is from the study by (Malik et al., 2012).   
  
Figure 2 
Functional analysis of differentially expressed genes (FDR adjusted p ≤ 0.1 and fold change ≥ 
1.5 in either direction) using IPA for lung (a) and liver (b). The Ingenuity Pathway Analysis 
Knowledge Base was used to identify biological functions and/or diseases that were significantly 
over-represented among the differentially expressed genes. A right-tailed Fisher’s exact test was 
used to calculate a p value determining the probability that each biological function and/or 
disease assigned to that data set was due to chance alone (threshold set at p value < 0.05).  
 
Figure 3 
Molecular relational network of genes modulated by BaP in lung tissues enriched for cancer 
function using IPA for all three doses with p53 at the central node. A network is a graphical 
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representation of the molecular relationships between molecules. Molecules are represented as 
nodes and the biological relationship between two nodes is represented as a line. The gene list 
was derived from cancer-associated genes determined in the Ingenuity Pathway Analysis 
functional analysis of significantly differentially expressed genes (Figure 2). The networks were 
generated from cancer-associated genes differentially regulated in the 25 mg/kg/day (green 
circle), 50 mg/kg/day (blue circle), and 75 mg/kg/day (pink circle) dose groups. Red colour 
denotes upregulation and green colour denotes downregulation. 
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TABLES 
Table 1  
Agilent probes with FDR adjusted p value ≤ 0.05 common to all three dose groups as measured by microarrays on lung tissue. Fold changes 
relative to control are shown. The most commonly associated gene function  is provided. ↑ indicates upregulated, ↓ indicates downregulated, 
Agilent Probe ACCESSION # GENE SYMBOL Function 25 mg/kg/day 50 mg/kg/day 75 mg/kg/day 
A_52_P612803 NM_009831 Ccng1 Cell Cycle ↑ 1.8 ↑ 3.3 ↑ 4.6 
A_51_P363947 NM_007669 Cdkn1a Cell Cycle ↑ 2.5 ↑ 5.7 ↑ 9.3 
A_51_P472751 NM_007915 Ei24 Apoptosis ↑ 1.4 ↑ 1.8 ↑ 2.1 
A_51_P508289 NM_010145 Ephx1 Xenobiotic Metabolism ↑ 1.7 ↑ 2.3 ↑ 2.9 
A_52_P532982 NM_011819 Gdf15 Cellular Differentiation and Proliferation ↑ 2.6 ↑ 6.9 ↑ 9.1 
A_51_P468173 NM_008251 Hmgn1 DNA Damage Repair ↑ 1.3 ↑ 1.5 ↑ 1.5 
A_51_P167489 XM_140451 Lama3 Cell Adhesion ↑ 1.6 ↑ 1.5 ↑ 1.5 
A_51_P484111 NM_016762 Matn2 Unknown Function ↓ 1.5 ↓ 1.5 ↓ 1.9 
A_51_P463562 NM_008620 Mpa2 Possibly Cellular Differentiation ↑ 1.4 ↑ 1.5 ↑ 1.8 
A_52_P13389 NM_026793 Myct1 Possibly Apoptosis ↑ 1.6 ↑ 1.8 ↑ 1.9 
A_51_P195875 NM_010929 Notch4 Cellular Differentiation   ↑ 1.6 ↑ 1.7 ↑ 1.8 
A_51_P363801 NM_023217 Pgpep1 Proteolysis ↑ 1.3 ↑ 1.6 ↑ 1.5 
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A_51_P329928 NM_013750 Phlda3 Apoptosis ↑ 2.1 ↑ 3.8 ↑ 5.1 
A_51_P224564 NM_176833 Ppm1f Apoptosis ↑ 1.4 ↑ 1.5 ↑ 2.0 
A_51_P227392 NM_133955 Rhou Cell Cycle ↓ 1.6 ↓ 1.6 ↓ 1.5 
A_51_P246903 NM_026467 Rps27l Apoptosis/DNA Damage Repair ↑ 1.4 ↑ 1.8 ↑ 2.5 
A_51_P319572 NM_001037709 Rusc2 Unknown Function ↑ 1.3 ↑ 1.5 ↑ 1.7 
A_51_P415755 AK052232 Sema6d Cellular Differentiation ↑ 1.4 ↑ 1.4 ↑ 1.5 
A_52_P154710 AK170547 Sesn2 DNA Damage Repair ↑ 1.7 ↑ 2.7 ↑ 3.8 
A_52_P220810 NM_144551 Trib2 Cellular Proliferation ↑ 1.4 ↑ 1.9 ↑ 2.1 
A_51_P175580 NM_021897 Trp53inp1 Apoptosis ↑ 1.6 ↑ 2.5 ↑ 2.9 
A_52_P503387 NM_021897 Trp53inp1 Apoptosis ↑ 1.6 ↑ 2.3 ↑ 2.9 
A_51_P509609 NM_053082 Tspan4 Cell Signaling ↑ 1.7 ↑ 1.7 ↑ 1.8 
A_51_P155052 NM_053247 Xlkd1 Metastasis ↑ 2.2 ↑ 2.3 ↑ 3.2 
A_52_P686785 NM_053247 Xlkd1 Metastasis ↑ 2.1 ↑ 2.1 ↑ 3.6 
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Table 2 
P53 regulated genes that were significantly differentially expressed with microarrays and real-time PCR in lungs. Only genes with FDR 
adjusted p ≤ 0.1 and fold change ≥ 1.5 are shown. Gene symbols in bold were also differentially expressed in liver (Malik et al., 2012). ↑ 
indicates upregulated, - indicates no change.  
Gene 
Symbol 
25 mg/kg/day 50 mg/kg/day 75 mg/kg/day 
Microarray RT-PCR Microarray RT-PCR Microarray RT-PCR 
Cdkn1a ↑ 2.5 ↑ 3.2 ↑ 5.7 ↑ 8.1 ↑ 9.3 ↑ 12.6 
Ccng1 ↑ 1.7 ↑ 2.2 ↑ 3.1 ↑ 3.0 ↑ 4.6 ↑ 4.3 
Trp53inp1 ↑ 1.6 ↑ 1.8 ↑ 2.4 ↑ 2.1 ↑ 2.9 ↑ 3.2 
Sesn2 - ↑ 2.9 ↑ 2.2 - ↑ 2.7 ↑ 3.4 
Bax ↑ 1.5 ↑ 1.9 ↑ 1.9 ↑ 2.5 ↑ 2.5 ↑ 3.4 
Pmaip1 - - ↑ 1.7 ↑ 1.7 ↑ 1.7 ↑ 1.8 
Mdm2 - - - ↑ 1.8 ↑ 1.6 ↑ 2.7 
Bcl2 - - - - - ↑ 1.5 
Ccnb2 - - - ↑ 1.7 - ↑ 1.9 
Tnfrsf10b - ↑ 2.0 - ↑ 2.7 - ↑ 4.4 
Zmat3 - ↑ 1.8 ↑ 1.8 ↑ 1.7 ↑ 2.7 ↑ 2.5 
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Table 3 
Genes validated using real-time PCR arrays divided based on functional association in lungs. Only genes with FDR adjusted p ≤ 0.1 and fold 
change ≥ 1.5 are shown. ↑ indicates upregulated, ↓ indicates downregulated, - indicates no change. Genes with an asterix (*) indicate genes 
significantly differentially expressed by the PCR array but not significant by microarray. Please note that some genes appear more than once 
because they are implicated in several functions. 
Function Gene Symbol 25 mg/kg/day 50 mg/kg/day 75 mg/kg/day 
  Microarray RT-PCR Microarray RT-PCR Microarray RT-PCR 
P53 Signalling 
 
Cdkn1a ↑ 2.5 ↑ 3.2 ↑ 5.7 ↑ 8.1 ↑ 9.3 ↑ 12.6 
Tnfrsf10b* - ↑ 2.0 - ↑ 2.7 - ↑ 4.4 
Ccng1 ↑ 1.7 ↑ 2.2 ↑ 3.1 ↑ 3.0 ↑ 4.6 ↑ 4.3 
Bax ↑ 1.5 ↑ 1.9 ↑ 1.9 ↑ 2.5 ↑ 2.5 ↑ 3.4 
Sesn2 - ↑ 2.9 ↑ 2.2 - ↑ 2.7 ↑ 3.4 
Trp53inp1 ↑ 1.6 ↑ 1.8 ↑ 2.4 ↑ 2.1 ↑ 2.9 ↑ 3.2 
Mdm2 - - - ↑ 1.8 ↑ 1.6 ↑ 2.7 
Zmat3 - ↑ 1.8 ↑ 1.8 ↑ 1.7 ↑ 2.7 ↑ 2.5 
Ccnb2* - - - ↑ 1.7 - ↑ 1.9 
Pmaip1 - - ↑ 1.7 ↑ 1.7 ↑ 1.7 ↑ 1.8 
Bcl2* - - - - - ↑ 1.5 
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B cell Receptor 
Signalling 
 
Cd3g* - - - - - ↓ 1.7 
Cxcr5* - - - - - ↓ 1.5 
Dock2* - - - - - ↓ 1.5 
Tnfsf10 - ↑ 1.5 ↑ 1.8 - ↑ 1.8 ↑ 1.5 
Calcium Signalling 
 
Penk* - ↑ 2.5 - - ↓ 2.4 ↑ 2.4 
Cyr61 - ↑ 1.5 - ↑ 1.8 ↑ 1.9 ↑ 1.8 
Adrb1 - ↑ 1.7 - - ↑ 1.9 ↑ 1.7 
Slc30a1 - - ↑ 1.5 - ↑ 1.5 ↑ 1.7 
S100a8* - ↓ 1.6 - - - - 
Pln* - ↓ 2.4 - - - - 
Per1* - ↑ 2.4 - - - - 
Transforming Growth 
Factor Signalling 
 
Ccnb2 - - - ↑ 1.7 - ↑ 1.9 
Ctgf - ↑ 1.7 - ↑ 1.6 ↑ 1.8 ↑ 1.9 
Cyr61 - ↑ 1.5 - ↑ 1.8 ↑ 1.9 ↑ 1.8 
Eng* - ↑ 1.8 - ↑ 1.5 - ↑ 1.6 
Jun* - ↑ 1.5 - - - ↑ 1.6 
Igf1* - - - - - ↑ 1.5 
Tgfb1* - - - - - ↑ 1.5 
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Cell Cycle and DNA 
Damage Repair 
 
Cdkn1a ↑ 2.5 ↑ 3.2 ↑ 5.7 ↑ 8.1 ↑ 9.3 ↑ 12.6 
Sesn2 - ↑ 2.9 ↑ 2.2 - ↑ 2.7 ↑ 3.4 
Mdm2 - - - ↑ 1.8 ↑ 1.6 ↑ 2.7 
Mgmt* - - - ↑ 2.0 - ↑ 2.7 
Ccnd1 - - ↑ 1.7 ↑ 1.8 ↑ 2.3 ↑ 2.5 
Polk - - ↑ 1.6 ↑ 1.6 ↑ 1.9 ↑ 1.8 
Tgfb1 - - - - - ↑ 1.5 
Prc1* - ↑ 1.5 - - - - 
Apoptosis 
 
Tnfrsf10b* - ↑ 2.0 - ↑ 2.7 - ↑ 4.4 
Bax ↑ 1.5 ↑ 1.9 ↑ 1.9 ↑ 2.5 ↑ 2.5 ↑ 3.4 
Trp53inp1 ↑ 1.6 ↑ 1.8 ↑ 2.4 ↑ 2.1 ↑ 2.9 ↑ 3.2 
Bcl2l1 - - - ↑ 1.7 ↑ 1.6 ↑ 2.3 
Tnfrsf1a* - - - - - ↑ 1.7 
Bcl2* - - - - - ↑ 1.5 
Tgfb1* - - - - - ↑ 1.5 
Tnfsf10 ↑ 1.5 ↑ 1.5 ↑ 1.8 - ↑ 1.8 ↑ 1.5 
Cidea* - ↑ 2.7 - - - - 
Card6* - ↑ 1.5 - - - - 
 43
Angiogenesis 
 
Col18a1 - - - ↑ 1.5 ↑ 1.8 ↑ 2.1 
Cyr61 - ↑ 1.5 - ↑ 1.8 ↑ 1.9 ↑ 1.8 
Kdr* - - - - - ↑ 1.8 
Pdgfa* - ↑ 1.7 - ↑ 1.5 - ↑ 1.8 
Vegfc* - ↑ 1.6 - - - ↑ 1.7 
Pecam1* - - - - - ↑ 1.7 
Igf1 - - - - - ↑ 1.5 
Pdgfb - ↑ 1.5 - - ↑ 1.6 ↑ 1.5 
Tgfb1* - - - - - ↑ 1.5 
Vegfa* - ↑ 1.5 - - - - 
F2* - ↑ 2.9 - - - - 
Plg* - ↑ 1.9 - - - ↑ 1.8 
Invasion and 
Metastasis 
Serpine1 - ↑ 1.8 ↑ 2.0 ↑ 3.3 ↑ 2.8 ↑ 5.0 
Plau* - ↑ 2.8 - ↑ 2.9 - ↑ 3.1 
Mmp2 - - - - ↑ 1.5 ↑ 1.9 
Twist1* - ↓ 2.9 - - - - 
Adhesion 
 
Pecam1 - - - - - ↑ 1.7 
Itga3* - - - - - ↑ 1.5 
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Signal Transduction 
 
Jun - ↑ 1.5 - - - ↑ 1.6 
Myc - - - ↓ 1.5 - - 
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Table 4 
Cancer pathway (KEGG) associated genes significantly differentially expressed in microarrays in the lung and not in the liver. Only genes 
with FDR adjusted p ≤ 0.05 and fold change ≥ 1.5 are shown. ↑ indicates upregulated, ↓ indicated downregulated, - indicates no change.  
Gene 
Symbol 25 mg/kg/day 50 mg/kg/day 75 mg/kg/day 
Gene 
Symbol 25 mg/kg/day 50 mg/kg/day  75 mg/kg/day 
Bax - ↑ 1.9 ↑ 2.5 Map4k4 - - ↑ 1.8 
Bcl2l1 - - ↑ 1.6 Mdm2 - ↑ 1.7 ↑ 2.2 
Bdnf - - ↑ 1.5 Myc - - ↓ 1.6 
Bmp6 - - ↑ 1.5 Nkd1 - ↑ 1.7 ↑ 1.9 
Ccl5 - - ↓ 2.1 Ntrk2 - - ↓ 1.6 
Cd47 - - ↓ 1.5 Pdgfd - - ↑ 1.5 
Col4a1 - - ↑ 1.7 Pdgfd - - ↑ 1.5 
Col4a2 - - ↑ 1.7 Pdgfra - - ↓ 1.5 
Cpt1b - - ↓ 1.6 Pmaip1 - ↑ 1.7 ↑ 1.8 
Cpt1c - - ↑ 1.9 Ptprm - - ↑ 1.6 
Dcn - - ↓ 2.4 Rasgrp3 - - ↑ 1.8 
Ei24 - ↑ 1.8 ↑ 2.1 relA - - ↑ 1.6 
Flnc - - ↓ 1.7 Serpine1 - ↑ 2.0 ↑ 2.8 
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Gp9 - ↑ 1.8 ↑ 1.5 Sesn2 ↑ 1.7 ↑ 2.7 ↑ 3.8 
Itga1 - - ↑ 1.5 Smurf2 - ↑ 1.6 - 
Kitl - ↑ 1.6 ↑ 1.6 Tnfrsf12a - - ↑ 1.7 
Lama3 ↑ 1.6 ↑ 1.5 ↑ 1.5 Tnfsf10 - ↑ 1.8 ↑ 1.8 
Lamb3 ↑ 1.5 ↑ 1.5 ↑ 1.6 Ubc - - ↑ 1.5 
Lamc2 - - ↑ 1.6 Wnt10a - ↓ 1.6 ↓ 1.6 
Ltb - - ↓ 1.5 Wnt7a - - ↑ 1.8 
Map4k1 - - ↓ 1.5     
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Table 5  
P53 regulated genes identified in liver by Malik et al. (2012) were cross validated in the lung using real-time PCR arrays. Only genes with 
FDR adjusted p ≤ 0.1 and fold change ≥ 1.5 are shown. ↑ indicates upregulated, ↓ indicates downregulated, - indicates no change.  
Gene 
Symbol 
25 mg/kg/day 50 mg/kg/day 75 mg/kg/day 
Lung Liver Lung Liver Lung Liver 
Cdkn1a ↑ 3.2 - ↑ 8.1 ↑ 6.8 ↑ 12.6 ↑ 16.9 
Tnfrsf10b ↑ 2.0 - ↑ 2.7 ↑ 3.7 ↑ 4.4 ↑ 7.8 
Egr - - - ↑ 4.1 - ↑ 6.4 
Btg2 - - - ↑ 2.2 - ↑ 3.4 
Ccnb2 - - ↑ 1.7 - ↑ 1.9 ↑ 2.4 
Zmat3 ↑ 1.8 - ↑ 1.7 ↑ 1.6 ↑ 2.5 ↑ 2.4 
Apaf1 - - - ↑ 1.8 - ↑ 2.2 
Prc1 - - - - - ↑ 1.9 
Ccng1 ↑ 2.2 - ↑ 3.0 - ↑ 4.3 ↑ 1.8 
Birc5 - - - - - ↑ 1.8 
Myod - ↓ 2.1 - ↓ 1.6 - ↓ 1.6 
Bax ↑ 1.9 - ↑ 2.5 - ↑ 3.4 ↑ 1.7 
Trp63 - ↓ 2.1 - ↓ 2.5 - - 
 Figure 1 
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